Background: Patients with treatment-resistant depression (TRD) suffer very significant morbidity and are at a disadvantage concerning optimal clinical management. There are high associated societal costs.
Introduction
Currently, depression is estimated to affect approximately 121 million people worldwide and is associated with approximately 850,000 deaths by suicide every year.
It is the leading cause of disability and is expected to be the second leading contributor to the global disease burden by 2020 (Demyttenaere et al., 2004; WHO, 2010) . Key costs of depression include treatment costs and the costs associated with family care and lost employment. The economic burden of major depressive disorder (MDD) was estimated at $124 billion in the USA in 2012 (Mrazek et al., 2014) and €118 billion in Europe in 2004 (Richards, 2011) . In England, in 2007, the total cost of services for depression was estimated to be in the region of £1.7 billion; adding lost employment increased this by a further £5.8 billion (McCrone et al., 2008) . Between 10% and 20% of patients with a major depressive episode (Kessler et al., 2003; Kubitz et al., 2013) will go on to suffer more complex and protracted forms of depression, with poor responses to treatment and major effects on work functioning, interpersonal relationships, and quality of life (Greden, 2001) . These forms are frequently termed treatment-refractory or treatment-resistant depression (TRD). However, while there appears to be a general consensus on the definition of chronic depression (a minimum of a 2-year period), there are inconsistencies surrounding the definition of TRD (Berlim & Turecki, 2007) . These inconsistencies make it difficult to discern its actual prevalence. High rates of non-response of depressed patients to treatments in general have been reported (Simon et al., 2002; Thomas et al., 2013) , with 12-20% of depressed patients not benefiting even from multiple courses of treatment (Kubitz et al., 2013) .
These patients have also been found to make a disproportionate contribution to the economic burden associated with the spectrum of depressive disorders (Crown et al., 2002; Ivanova et al., 2010) . For example, studies suggest that compared with patients Running Head: Economic Cost of TRD suffering from chronic depression, patients with TRD have significantly higher costs for imaging tests, physician visits and psychiatric hospitalization (Fostick et al., 2010) , as well as for direct medical expenditures (Olchanski et al., 2013) .
The aim of this study is to investigate the costs associated with this patient group in the United Kingdom (UK). The sample consisted of participants from the Tavistock Adult Depression Study (TADS; Fonagy et al., 2015) , who were referred from primary care with a diagnosis of MDD of at least 2 years' duration and at least two failed treatment attempts. Specifically, we aimed: (i) to measure service use and lost employment and their associated costs over the 1-year period before randomization into the study; and (ii) to identify any particular clinical and demographic characteristics associated with these costs.
Method

Data and study design
This study was a retrospective analysis of service use and costs of the participants recruited to the TADS. The TADS was a pragmatic randomized controlled trial set up to investigate the effectiveness of long-term psychoanalytic psychotherapy (LTPP) compared with treatment as usual (TAU) delivered according to UK national guidelines as arranged by the participants' primary care providers. Detailed descriptions of the study design and outcome findings are available elsewhere (Fonagy et al., 2015; Taylor et al., 2012) . In brief, participants were recruited from GP practices from central and Interview for DSM-IV (SCID-I; First et al., 2001) ; reported a minimum duration of 2 years of the current depressive episode; scored a minimum of 14 on the 17-item version Running Head: Economic Cost of TRD of the Hamilton Rating Scale for Depression (HRSD; Hamilton, 1967) and 21 on the Beck Depression Inventory (BDI-II; Beck et al., 1996) ; and had at least two failed treatment attempts, one of which must have included an antidepressant medication (ADM), while the other could include either an ADM from a different class or a psychological therapy. Patients with a diagnosis of psychotic disorder, bipolar disorder, psychiatric input for substance abuse or dependency, mild or severe learning disability, and evidence of organic brain disorder were excluded. Ethical approval was sought and approved by the Institutional Review Board of the NHS West Midlands Research Ethics Committee (MREC02/07/035).
Service use and cost
Participants recruited into the trial (n=129) completed an adapted version of the Client Service Receipt Inventory (CSRI; Beecham & Knapp, 2001) as part of a comprehensive assessment, and consented to the study accessing their GP medical records. The information in the CSRI was provided by the participants and covered the 12-month period before randomization into the trial. Information collected included: number and duration of contacts with primary and secondary health and social care services; unpaid informal care received, such as help with child care, personal care, help in and around the home, and help outside the home; employment status; and days of lost employment.
The same information was also extracted from the participant's medical records by two independent researchers. To achieve reliability of data extraction, a third researcher clarified any discrepancies and an average was calculated in cases of a confirmed major difference. For the current analysis, both data sources were combined. A societal perspective was adopted in which both costs to the health and social care system and the broader impacts on productivity and families were included. Service use data were combined with nationally representative information on unit costs. For most services these unit costs were drawn from an annually updated source (Curtis, 2010) . Hospital costs were obtained from routine data collected by the UK Department of Health (Department of Health, 2011) . For the cost of informal care we used an average hourly wage rate of £14.60; lost employment costs were calculated using an average daily wage rate of £97.52 (Office for National Statistics, 2011). Running Head: Economic Cost of TRD
Data analysis
Analyses were conducted on all cases providing service use data. These were baseline data and so no imputation for missing cases was conducted. However, where quantities of specific service use was missing we used median values for others using that services. Descriptive statistics were produced for socio-demographic characteristics; length and severity of depression; functioning, as measured with the Global Assessment of Functioning Scale (GAF; Hilsenroth et al., 2000) ; and Generalized Anxiety Disorder (GAD), as measured with the SCID-I (First et al., 2001) , coded here as a binary variable comparing moderate or severe versus mild or no levels. The number and percentage of participants using specific services is reported and the mean number and standard deviation (SD) of contacts by those who used them, as well as the mean and SD cost for the whole sample (i.e. including those not using specific services). Univariate descriptive analyses were conducted to observe the relationship between demographic and clinical characteristics and cost categories (healthcare, informal care plus lost employment, and total cost). This was followed by regression analyses using the same variables and cost categories, using Stata version 11. As costs tend to follow a skewed distribution, we used generalized linear models with a gamma family and log link function (Mihaylova et al., 2011) in order to identify cost predictors. This was due to the positively skewed cost distribution. In these exploratory analyses statistical significance was assumed at the P<0.1 level.
Results
Characteristics of the sample 6
Running Head: Economic Cost of TRD Of the 129 participants randomized into the study, health economic data were available for 118 (91.5%). Table 1 provides a summary of their socio-demographic and diagnostic characteristics. As per protocol, all patients had a diagnosis of current MDD; 76% had an additional diagnosis of early-onset dysthymia and 37% had a comorbid diagnosis of GAD (13% mild and 25% moderate/severe levels). The average total duration of depression was 25.4 years (SD=12.42) and the average length of the current depressive episode was 3.7 years (SD=3.01). In terms of depression severity, 75% scored within the severe range on the BDI-II (mean=36.2, SD=9.8) and 64% within the severe-very severe range on the HRSD-17 (mean=21.4, SD=5.6). The mean GAF score was 48.7 (SD=7.6) indicating serious functional impairment. The characteristics of the 118 participants for whom we obtained cost data were very similar to those of the 129 participants comprising the full sample (details available from the authors). Service use and costs Table 2 shows the number of the sample using specific services and, for those who had use, how many times on average this occurred. Costs are also shown for the whole sample. Only a small number of participants had been psychiatric inpatients in the 12 months before joining the trial; however, one in six had had hospital admissions for physical health problems. All patients reported having had GP contacts: their average frequency was slightly less than one per month. More than two-thirds of the sample had practice nurse contacts; a similar number had outpatient contacts for physical health problems. Nearly half the sample reported receiving informal care from family/friends in the previous 12 months due to their health problems. Two-thirds of participants had had lost employment due to health problems (either days off sick or out of work). 8 Running Head: Economic Cost of TRD The services with the highest mean costs were inpatient care, outpatient visits, day hospital attendances and GP contacts. Together, they accounted for 70% of the total average healthcare cost of £4388 (SD=£7347). However, informal care from family/friends was responsible for a higher proportion of the costs than those of health and social care services, and lost employment in particular was responsible for over twice the amount for health and social care. These social and employment categories accounted for 26% and 54%, respectively, of the total mean cost of £22,124 (SD = £23,466).
Health and social care services costs were somewhat higher for women than for men; this gender difference held for informal care and lost employment costs as well (see Table 3 ). Participants in the 41-50 and 51-60 age groups had the highest health and social care costs. Costs were also higher for married/cohabiting participants and those of non-white ethnicity. Costs associated with informal care and lost employment were highest for those aged 31-40. Overall costs were highest for participants who were unemployed. Participants with higher baseline depression severity had higher costs than those whose depression was less severe. Better functioning, as measured with the GAF, was associated with lower formal health and social care costs; the association between GAF and the costs of informal care and lost employment was less clear. Running Head: Economic Cost of TRD Table 3 Univariate analysis of costs (in 2009/10, £)
Characteristic
Health with lower health and social care costs: a one-unit increase in the GAF was associated with a 3% reduction in costs. The costs associated with informal care and lost employment of participants aged 31-40 were significantly higher than those aged [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Married/cohabiting participants had higher costs than those who were single, widowed, or divorced. If baseline depression severity scored 40 or above on the BDI-II then informal care and lost employment costs were significantly increased. Again, the GAF score was inversely related to cost. Total costs were positively related to those aged 31-40, 41-50 and 51-60, participants who were married/cohabiting and those from a non-white ethnic group. Running Head: Economic Cost of TRD 
Discussion
This study measured the service use and costs over a 1-year period for patients with severe and complex forms of depression, commonly referred to as TRD. We found that the mean annual cost for individuals in this patient group in 2009/10 prices was high, at £22,124. This is comparable to the costs associated with dementia and schizophrenia (McCrone et al., 2008) . In current (2015/16) prices the figure would be approximately £25,000. Our figures are at least seven times as high as those reported by another recent UK study evaluating costs in a sample of patients suffering from TRD using a societal perspective (Hollinghurst et al., 2014) . However, differences in the definition of TRD Running Head: Economic Cost of TRD indicate that the sample in that study was less severely affected than ours. This difference emphasizes the need for precision in terms of defining the characteristics of these patients and the importance of establishing a commonly accepted definition of TRD.
The prevalence of depressive episodes in the general adult population of England has been reported to be 2.3% (McManus et al., 2009) , indicating that in 2016 the total number of individuals with depression in England was estimated to be 1.3 million (McCrone et al., 2008) . Epidemiological studies in the UK, like those of other countries (see Bromet et al., 2011) , reveal that in many patients depression does not remit completely. Studies of the natural course of depression generally find that half of patients will still meet diagnostic criteria after a year (Simon et al., 2002) . This corresponds to the sample whose costs were evaluated in the study of Hollinghurst et al. (2014) . However, on the basis that 12% of depressed patients (Andrade et al., 2003) fall into a category resembling that corresponding to the definition of TRD employed in our study, the costs in the UK of this part of the depressive spectrum can be estimated to be in the region of £3.9 billion. In the present study, lost employment and informal care costs were found to account for 54% of the total, and formal service and treatment costs for only 26%. The dominance of lost employment costs agrees with the findings of previous studies (e.g. Broadhead et al., 1999; Curran et al., 2007; Kessler & Frank, 1997) . The most expensive formal service costs were those for physical inpatient and outpatient care, and GP contacts. Notably, in spite of the evident severity of the condition suffered by this patient group, surprisingly few were admitted to hospital for psychiatric care.
In exploring the variations in costs between individuals, we found that level of functioning was significantly and inversely related to health/social care costs and also to Running Head: Economic Cost of TRD informal care/lost employment costs. The strength of this relationship may have reduced the figure for the impact of depression symptom severity on costs; the latter was statistically significant only for informal care/lost employment. Given that these latter costs account for the larger fraction of the total costs, points to the important possibility that treatments whose mode of action aims to directly reduce the level of functional impairment (or, conversely, increase functional capacity) may more effectively reduce the economic burden of TRD than those thought to act on symptoms more narrowly. Andrews (2001) concluded that the burden of disease attributable to depressive disorders has not fallen in higher-income countries even though evidence-based treatments deemed to address mental state symptoms have become more widely available. Likely this will apply to TRD patients. Finally, it might seem counterintuitive that total costs were found to be higher for those who were married/cohabiting. Most likely this reflects the greater availability of informal care for these participants rather than indicating the existence of an intrinsic difference between married/cohabiting patients and those living alone.
Limitations
Unfortunately, while the GAF is widely used as a proxy of both functioning and symptoms, it has severe limitations as a measure of the many domains involved in functional capacity/impairment (Dimsdale et al., 2010; Smith et al., 2011) . In addition to the GAF, we used participant self-report of service use data supplemented by information from medical records. Both sources may not be fully accurate. Recall accuracy can be a problem for self-report data, although studies have shown it to be a reasonable approach (Calsyn et al., 1993; Goldberg et al., 2002) . Administrative records may be more accurate for some services (e.g. GP contacts, days in hospital), but may not capture as broad a range of data as self-reporting. Running Head: Economic Cost of TRD A second limitation is that the study was carried out in a particular area of London, albeit one with diverse populations and spanning many socioeconomic conditions, and that the sample consisted of those referred for specialist care. Generalizing the findings to other settings and healthcare systems needs thus to be done cautiously. Given its high costs, this is especially pertinent to inpatient care.
Third, the costs reported included all services used by patients with TRD and not necessarily those used specifically because of TRD. As shown, one in six of the participants accessed services in connection with physical health problems. The existence of complex interactions between depression, physical symptoms, and physical illness is well known. Individuals diagnosed with depression have been found to have higher comorbidity with physical problems and vice versa (e.g. Choi et al., 2014; Smith et al., 2011; Stegmann et al., 2010) . A matched comparison of groups of non-depressed and depressed non-TRD participants, controlling for physical health/illness, would be required to tease apart the impact of physical and mental health problems.
Conclusion
Despite these limitations, the findings of the present study highlight that severe forms of TRD are associated with high costs, in which unpaid care and lost work predominate.
Our findings support the idea that research on treatments that might act on the mechanisms that may exist between impaired levels of functioning and vulnerability to ongoing depression would be particularly valuable.
